Product diversion moves genuine medicines out of their intended channel, price tier or patient group; it is distinct from counterfeiting but opens routes for falsified stock.
Five types matter: access-programme leakage, tender leakage, cross-border parallel trade, channel and territory leakage, and diversion as a gateway for falsification.
Tiered pricing, long distribution chains, cash payment and partial serialization make emerging markets structurally exposed.
Regulation such as EU FMD, US DSCSA and India's Schedule H2 proves a pack is genuine, not that it is in the right channel.
Effective control links primary sales, secondary sales, scans and patient records, with one measurable signal per hand-off.
Diversion control and supply reliability use the same data, so programmes work best when funded as supply-chain projects.
Why product diversion needs its own playbook
Product diversion happens when a genuine medicine leaves the channel, price tier or patient it was intended for. In emerging markets it is often harder to see than counterfeiting, because the product in the diverted box is real.
This post sets out a working taxonomy of diversion, explains why emerging markets are structurally exposed, reviews the regulatory landscape, and proposes a control-point framework that manufacturers can measure. It closes with open questions where industry data could help researchers.
A working taxonomy of product diversion
Diversion is not one behaviour but five, and each leaves a different data trail. Treating them as one problem is why many anti-diversion programmes measure the wrong thing.
Type
What moves
Typical trigger
Where it surfaces
Access-programme leakage
Free or subsidised stock from patient assistance or donation programmes
Gap between programme price and retail price
Programme units dispensed without a matching verified patient
Tender and institutional leakage
Stock priced for government or hospital tenders
Tender price far below private-market price
Retail sales of tender-only packs; spikes in tender volumes
Cross-border parallel trade
Stock priced for one country, resold in another
Price differentials between neighbouring markets
Serial numbers scanned outside the intended geography
Channel and territory leakage
Stock sold to one distributor tier or territory, resold into another
Distributor incentives, schemes and free-goods offers
Primary sales that never appear in secondary sales
Diversion as a gateway for falsification
Genuine packaging or partial stock mixed with falsified product
Weak verification at the point of dispensing
Duplicate or unknown serial numbers; repackaged goods
Parallel trade is legal in some jurisdictions, such as within the EU single market. This post uses "diversion" for movement that breaks the terms under which stock was supplied, whether contractual, programme-based or regulatory.
Why emerging markets are structurally exposed to diversion
Diversion in emerging markets is mainly an incentive problem made invisible by a data problem. Four structural features combine to create it.
Tiered pricing creates the arbitrage. The same molecule often sells at a programme price, a tender price and a private-market price within one country. Neighbouring countries add further tiers. Every gap between tiers is a margin someone can capture by moving stock across it.
Distribution is long and fragmented. A pack may pass from manufacturer to carrying-and-forwarding agent, super-stockist, distributor, sub-distributor and retailer. Manufacturers usually see only the first sale, the primary sale, to their direct distributor. Everything after that, the secondary and tertiary sales, is visible only if distributors report it.
Manufacturers usually see only the primary sale to their direct distributor. Secondary and tertiary sales further down the chain are visible only if distributors report them.
Cash payment and out-of-pocket spending dominate. Where patients pay directly, there is no insurer claim trail to show which patient received which pack. In reimbursement-led markets, that claim trail does part of the detection work.
Serialization mandates are recent and partial. Many markets have authentication rules that let a pack be verified, but not full track-and-trace with aggregation and a central repository. A code that proves a pack is genuine does not, on its own, prove it is in the right channel.
What diversion costs patients, programmes and manufacturers
The heaviest cost of diversion falls on patients, not on manufacturer revenue. It shows up in four ways.
Patient safety. Diverted stock leaves the controlled channel, so recalls, pharmacovigilance follow-up and storage controls no longer reach it. The grey channels it travels through are also how falsified product enters the supply.
Cold-chain integrity. Vaccines, biologics and many oncology products need controlled temperatures. Stock that moves through informal hands has no temperature history, so a genuine product may reach a patient degraded.
Access-programme sustainability. When subsidised or free stock leaks, the programme pays for patients it never served. Sponsors then tighten eligibility or shrink the programme, and genuine patients lose access.
Data blind spots. Diverted sales distort demand data. Manufacturers forecast from sales that did not reach the intended market, which drives stockouts in one territory and excess stock in another.
The regulatory landscape: authentication is not channel control
Most traceability regulation is built to stop falsified medicines, not diversion. It proves a pack is genuine; it rarely proves the pack is where it was meant to be.
Regime
What it requires
Status (as of Oct 2026)
Relevance to diversion
EU Falsified Medicines Directive
Unique identifier and anti-tampering device on most prescription packs; verification against a central repository at dispensing
In application since 9 February 2019
End-point verification catches duplicates, but not legal parallel trade
US DSCSA
Electronic, interoperable, package-level transaction data between trading partners
Small-dispenser exemption extended in August 2026 to 27 November 2027
Package-level ownership history is the closest model to channel visibility
India Schedule H2
Barcode or QR code on the label for authentication
Top 300 brands from 1 August 2023; expanded in June 2026 to all vaccines, antimicrobials, anti-cancer and NDPS drugs
Authenticates packs; no central track-and-trace repository for the original 300-brand scope
WHO GSMS
Global reporting of substandard and falsified products by national regulators
Operating since 2013
Captures falsification incidents, not diversion volumes
A pack code proves a medicine is genuine, not that it is in the channel or territory it was supplied for.
India's 2026 Schedule H2 expansion matters for diversion because it covers anti-cancer drugs and vaccines, the categories most often sold through access programmes and government tenders, where price tiers are widest. A manufacturer can now pair a regulatory pack code with its own channel data, without adding a second code to the pack.
Southeast Asian markets are moving at different speeds, and requirements vary by country. Manufacturers operating regionally should map each market's rules before designing controls.
A control-point framework for tackling product diversion
Diversion is stopped at the points where stock changes hands, not at the factory gate. The framework below assigns one control and one measurable signal to each hand-off, so leakage shows up as a gap between two records.
Stage
Control
Diversion types addressed
Signal to watch
1. Packaging
Serialize packs, and mark programme and tender stock with a distinct pack or code range
All
Programme or tender codes scanned anywhere outside their channel
2. Primary sale
Allocate stock against approved territory and channel; aggregate serials to cartons and shipments
Territory, cross-border
Orders that exceed a distributor's historical demand
3. Distributor and sub-distributor
Capture secondary sales and scans at each tier
Channel, territory
Primary sales that never appear in secondary sales
4. Institution or pharmacy
Verify the pack at receipt and at dispensing
Tender, falsification
Duplicate serials; tender packs dispensed at retail
5. Patient (access programmes)
Link each dispensed unit to a verified, enrolled patient
Programme leakage
Units issued per patient against expected dose and duration
6. Cross-chain analytics
Reconcile all records and rank exceptions
All
Risk score by distributor, territory and SKU
Each hand-off gets one control and one measurable signal, so leakage shows up as a gap between two records.
Three design choices decide whether a control-point framework works in practice.
Close the loop between programme and supply data. Access-programme leakage is visible only when dispensing records and patient records sit in the same system. If the patient support programme and the distributor management system are separate, the reconciliation in stage 5 never happens.
Make scanning cheaper than not scanning. Sub-distributors and small pharmacies will not scan for the manufacturer's benefit alone. Tie scans to something they value, such as faster credit notes, scheme payouts or replenishment.
Treat exceptions as investigations, not verdicts. A scan outside the expected territory may be legal parallel trade, a routing error or diversion. The system should rank exceptions for a person to review, not trigger automatic penalties.
On the Zelthy platform, these stages map to configurable distributor management modules: Distributor Management, Ordering Platform, Sales Data Capture, Temperature Data Capture and Track and Trace. Patient programme modules sit on the same platform, which is what allows stage 5 reconciliation.
Pack codes prove a box is genuine. What proves it's in the right channel?
Zelthy runs Distributor Management, Ordering, Sales Data Capture, Temperature Data Capture and Track and Trace on the same platform as patient programmes, so primary sales, secondary sales, scans and patient records reconcile in one place.
Controlled distribution is practical in emerging markets when it is built into how distributors already work. Zelthy powered India's first controlled distribution network for a pharma product, and a blockchain-based traceability deployment on the platform cut stockouts by 15% and sped up inventory turnover by 25%.
Results from a blockchain-based traceability deployment on the Zelthy platform.
Those results point to a lesson that is easy to miss: diversion control and supply reliability use the same data. When secondary sales and scans are captured at each tier, the manufacturer also gains a better demand signal. That is why the strongest programmes are funded as supply-chain projects, not only as compliance projects.
Metrics worth tracking from the first month:
Secondary-sales coverage: share of primary-sale volume later matched to a recorded secondary sale.
Scan compliance by tier: share of packs scanned at receipt, by distributor tier and territory.
Out-of-channel scan rate: programme or tender codes scanned outside their intended channel, per 10,000 packs.
Units per verified patient: for access programmes, dispensed units against the expected regimen.
Exception closure time: days from a flagged exception to a documented outcome.
Publish these diversion metric definitions internally before launch. Most programmes fail to show impact because no baseline was recorded.
Open research questions
Diversion in emerging markets is poorly measured, and that gap is where industry and academia can help each other. Four questions stand out:
Prevalence. How much programme and tender stock leaks, by therapy area and country? WHO's falsification estimates have no equivalent for diversion.
Diversion and falsification. How often does diverted genuine stock open a route for falsified product into the same channel?
Incentive design. Which distributor incentives raise scan compliance at the sub-distributor and retail tiers without adding cost to patients?
Access trade-offs. Do tighter anti-diversion controls in access programmes reduce leakage without lowering enrolment of eligible patients?
Conclusion
Product diversion is a channel problem, so it needs channel data. Pack codes prove authenticity, but only linked primary, secondary and patient records show where stock actually went. Manufacturers that connect those records can protect access programmes, reduce stockouts and give regulators better evidence.
Product diversion is the movement of a genuine medicine outside the channel, territory, price tier or patient it was supplied for. Examples include free access-programme stock sold at retail and tender stock resold to private pharmacies.
How is diversion different from counterfeiting?
Counterfeiting involves a fake product, while diversion involves a real product in the wrong place. The two are linked, because the grey channels that carry diverted stock also carry falsified stock.
Is parallel trade the same as diversion?
Not always. Parallel trade is legal in some settings, such as within the EU single market. It becomes diversion when it breaks the contractual, programme or regulatory terms under which stock was supplied.
Does serialization stop diversion?
Serialization helps but does not stop diversion alone. A pack code proves authenticity; detecting diversion also needs records of where each pack was sold, scanned and dispensed.
Which products are most at risk in emerging markets?
Products with the widest price gaps are most exposed, typically oncology drugs, vaccines and other medicines sold through access programmes or government tenders. India's 2026 Schedule H2 expansion covers several of these categories.
What should a manufacturer measure first?
Start with secondary-sales coverage, scan compliance by tier and the out-of-channel scan rate. Record a baseline before launch so the programme's impact can be shown.
Looking for traceability that sees past the primary sale?
Zelthy is pharma's traceability and controlled-distribution platform. It powered India's first controlled distribution network for a pharma product, and a deployment on the platform cut stockouts by 15% and sped up inventory turnover by 25%. Pair EU FMD, DSCSA or Schedule H2 pack codes with your own secondary-sales, scan and patient data to see where every pack actually went.
